Coactinon’s last act
Executive Summary
Triangle Pharmaceuticals terminates development of Coactinon (emivirine) after analysis shows non-nucleoside reverse transcriptase inhibitor did not perform as well as comparator drug abacavir (GlaxoSmithKline's Ziagen) across full study population in Phase III trial...
You may also be interested in...
Triangle Coviracil NDA Slated For September; Abbott Bows Out As Partner
Triangle Pharmaceuticals will file an NDA for Coviracil in September without a marketing partner following the reacquisition of rights to the nucleoside reverse transcriptase inhibitor from Abbott
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.